NUZ 0.00% 23.0¢ neurizon therapeutics limited

Seventy Reason to Buy PAA, page-270

  1. 2,422 Posts.
    lightbulb Created with Sketch. 1507
    What's the point of this post Bucky, we all bloody well know that most specs in everything are a failure. I mean honestly Bucky the only point about your post is to try and SCARE people with rank, basic statistics. I suppose tree shakers figure there are some who'll be worried by this and will be made to easily drop their bundle, otherwise I don't know why you bother.

    The reality here is thatt this new gen mTOR replacement treatment for RAPAMYCIN just keeps looking better and better with each and every test - but do you talk about that? Nah, just throw in the latest scary generic statistical story about biotech spec failures and every so often say "there's no progress" been made.

    Well sorry Buckland, but the latest announcement is that finally, after months of delays, there is the first full cohert of patients on MND, and thus far, none of the usual tolerability issues of those on mTOR treatments and now there going to escalate the dosage beginning with the first patients while they recruit the second cohert of patients. Progress is being made, Bucky. Sorry for giving you the GOOD NEWS.


 
watchlist Created with Sketch. Add NUZ (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.